


Giving dogs their smile back

Cimalgex® dosage 2mg/kg⁽¹⁾



Bodyweight	8 mg	30 mg	80 mg	
2				
3				
4				
5				
6				
7-8				
9-11				
12				
13-17				
18-22				
23-28				
29-33				
34-38				
39-43				
44-48				
49-54				
55-68				

Easy to dose, easy to give, easy to live

This dosing chart provides examples of how Cimalgex® multi-scored tablets can be used; the choice of the most suitable tablet type or tablet parts is left to the discretion of the veterinarian based on the circumstances in each case, without leading to important over or underdosing. Further information is available from the SPC which can be found on the following link: <https://www.ema.europa.eu/en/medicines/veterinary/EPAR/cimalgex#product-information-section>

it's my Cimalgex Smile



Convenience



Chewable, flavoured and multi-scored tablets for quick and accurate daily dosing.



Can be given with or without food.²



Three tablet strengths for all dog sizes and weight ranges.

Tolerance



No active cimicoxib is eliminated through the urine.³



Stable liver parameters in trials.^{4,5,6,7}



Good gastro-intestinal tolerance trial results.⁷

Efficacy



Proven efficacy in short-term and long-term pain management.^{4,6}



Rapidly available in the blood for effective pain reduction.¹



Cimalgex® contains cimicoxib. UK (POM-V). ROI (POM). Datasheets can be found on the NOAH or APHA websites (www.noahcompendium.co.uk / www.apha.ie/AnimalHealth/VeterinaryCompendium). Further information is available from the SPC which can be found on the following link: <https://www.ema.europa.eu/en/medicines/veterinary/EPAR/cimalgex#product-information-section>. Use medicines responsibly – see www.noah.co.uk for further details.

References: 1. Cimalgex® Summary of Product Characteristics. 2. R. Ollier, M. Schneider: Evaluation of the absolute bioavailability, and of the linearity of the kinetics of Cimicoxib in dogs, following a single oral administration of a tablet at a dose of 1, 2 and 4mg/kg, and influence of food on the bioavailability; 2008, Vetoquinol study. number no 3008P3F2/R. 3. Pena, Carbó, Merlos: In vivo metabolism of [14C] Cimicoxib in Beagle dog; Vetoquinol study number, CIN31102, 2003. 4. E. Grandemange (2013) Field evaluation of the efficacy and the safety of cimicoxib in the relief of perioperative pain in dogs. Journal of Small Animal Practice 54 (6), 304-312. 5. J. Zapatero, A. Casadesus, M. de Luna and C. Santasusagna: Toxicity in Beagle dogs with repeated administration for 5 weeks and a 14 day recovery period. Oral administration; 2002, Vetoquinol study number n°CD01/7674T. 6. S. Rougier (2008) Assessment of the efficacy and safety of cimicoxib compared to firocoxib in dogs with osteoarthritis. Vetoquinol Study n° V3008C1F1. 7. H. Voute: 26 week oral (tablets) safety study in the Beagle dog treated with Cimicoxib at 2, 6 and 10 mg/kg/day; 2009, Vetoquinol study number n° 3008T4F1.

Cimicoxib is supplied under licence from PALAU PHARMA, Spain.

Vetoquinol UK Limited, Steadings Barn, Pury Hill Business Park, Nr Alderton, Towcester, NN12 7LS.

+44 (0) 1280 814500 uk_office@vetoquinol.com www.vetoquinol.co.uk

vetoquinol
ACHIEVE MORE TOGETHER